Latest Global Manufacturing News

Skellerup Holdings delivered a tenth consecutive year of EBIT growth with a 14% rise to NZD 89.3 million and expanded its climate initiatives, reporting a 24% jump in net profit to NZD 67.7 million.

Sco Technology forecasts a record FY26 with revenue up to NZ$296 million and operating EBITDA reaching NZ$36 million, reflecting strong progress on its ambitious Destination 2030 growth plan.

IperionX plans to relocate its parent company to Texas and list directly on Nasdaq, aligning its corporate structure with its US operations. The appointment of manufacturing veteran Michael J. Loparco aims to bolster the company’s industrial scale-up.

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

EcoGraf confirms its patented HFfree process offers competitive costs for producing high-purity spherical graphite, targeting non-Chinese battery supply chains with plans for facilities in the US, Europe, and Asia.

archTIS delivered a 231% year-on-year increase in annual recurring revenue to A$15.1 million, marked by the full deployment of its US Department of Defense custom software and a significant contract with a US-European military alliance.

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

Orica Limited has resolved its US litigation with CF Industries by agreeing to a US$169.5 million settlement and is acquiring Nelson Brothers’ explosives business, strengthening its North American operations and boosting earnings.

Titomic Limited is planning to redomicile from Australia to the United States, aiming to deepen its footprint in the US defense and aerospace sectors and pursue a US stock exchange listing.

Orica reports solid first-half earnings growth led by digital and specialty chemicals, while launching a $100 million cost reduction program to navigate supply disruptions and litigation headwinds.